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Adler et al., in a paper appearing in Nature Genetics, exploited the intersect of genetic information from expression profiles 
with that from array comparative genomic hybridization in human breast cancers to identify genes that may induce the tran-
scription of the prognostic “wound response” expression signature. The amplification of two genes, MYC and CSN5, appeared 
to be correlated with the wound response cassette. In vitro validation showed that the wound signature could be induced in 
MCF10A cells only when MYC and CSN5 were coexpressed. This work shows that the intersect analysis of gene amplification 
and transcriptional expression on a genome-wide scale can uncover complex conditional interactions embedded in the sys-
tems map of transcriptional regulation.Since its inception, the promise of microarray technologies 
has been its potential to lay bare the molecular circuitry con-
trolling cellular pathways and disease states. Indeed, a “holy 
grail” of the expression array field has been the elucidation 
of pathway maps and the mechanisms underlying biological 
systems and pathological states from the output of a genome-
wide transcriptome analysis. However, with few exceptions, the 
microarray has fallen short of this promise—bona fide mecha-
nisms have remained elusive, while “candidate” genes have 
been identified by the thousands. Some of the reasons for 
this shortcoming relate to the maturity of the technical plat-
form (e.g., probe design and reproducibility), and to the state 
of knowledge of the transcriptome (from ESTs to full-length 
transcripts, to more advanced builds of the human genome 
sequence, to progressively better transcriptional representa-
tion of pathways). However, one of the problems is an underap-
preciation of array data dimensionality, which has limited the 
imagination in experimental design.
Array dimensionality can be defined by the complexity of 
the units of analysis. In its most basic form, arrays can be 
viewed as simple collections of individual probes. The analysis 
would therefore be focused on identifying an individual probe 
(or gene) associated with a phenotype. This analysis can be 
done with basic tools but has been troubled by irreproducibility 
across experimental systems, perhaps because of the inher-
ent imprecision of the technology, and from multiple sampling 
error. Higher-dimensional analysis assesses the behavior of 
clusters of genes using approaches such as principle compo-
nent analysis (PCA), and class prediction and feature selec-
tion procedures such as prediction analysis for microarrays 
(PAM) (Tibshirani et al., 2002), statistically weighted sysn-
dromes (SWS) (Kuznetsov et al., 1996; Broet et al., 2006), 
and significance analysis of microarrays (SAM) (Tusher et al., 
2001). Such approaches allow for the identification of coordi-
nately expressed genes with biological or clinical associations. 
Linkages with other databases such as protein-protein interac-
tion databases or Gene Ontology expand the dimensionality of 
the array data set to encompass biochemistry (protein interac-
tion) and biological functional (Gene Ontology). The successes 
from this approach have relied on raising hypotheses from 
these pathway analyses and confirmation by direct experi-
mentation. Thus, deciphering biological mechanisms requires 
looking beyond a single biological context and the unidimen-
sional view of gene expression. Moreover, the intersection of 
heterogeneous databases including diverse biological and 
clinical information provides higher-dimensional views of gene 
function and their clinical significance.
Adler and coworkers, in their work published in a recent 
issue of Nature Genetics (Adler et al., 2006), combined multiple 
cancer cell 9, April 2006 ©2006 ElsEviEr inc. genomics approaches with both in vitro and in vivo measure-
ments, to elucidate the causative transcriptional mechanisms 
responsible for a wound response signature that has prognostic 
significance in breast cancer. Building on previous work that 
identified a group of “wound response” genes coordinately 
induced in fibroblasts upon serum stimulation (Iyer et al., 1999) 
and subsequently found to be independently correlated with 
poor prognosis in breast cancer (Chang et al., 2005), Adler and 
colleagues correlated the wound response signature (defined by 
expression microarrays) to gene copy number changes (defined 
by array-CGH assessing chromosomal amplification) that might 
explain the transcriptional origin of the signature in aggressive 
breast cancer. Uniquely, they used the wound response expres-
sion cassette in a set of tumors as the dependent variable and 
asked what regions of gene amplification appeared to be cor-
related with this expression profile. The goal was to uncover the 
genetic components in amplicons that might transcriptionally 
control this wound response cassette. Adler and colleagues 
found that several genes on chromosome 8q were amplified in 
those tumors with the activated wound signature. In a larger set 
of 85 tumors for which they had wound scores derived from gene 
expression data, Adler et al. observed a number of genes on 
8q24 and 8q13 that showed a high correlation between expres-
sion and wound score. Looking at candidates with biological 
plausibility, they hypothesized that the oncogene MYC and 
CSN5, a general activator of the cullen ubiquitin ligase com-
plexes, both amplified in those tumors with the activated wound 
expression signature may functionally interact to regulate the 
transcription of the wound response cassette. Triangulation of 
these multiple nodes of genetic, genomic, and clinical informa-
tion, together with some literature-based reasoning, allowed 
the pinpointing of two candidate genes that the authors hypoth-
esized might interact functionally to modulate the wound sig-
nature genes.
To validate this, the authors overexpressed these two 
genes, MYC and CSN5, in MCF10A cells (derived from non-
cancerous human breast epithelial cells). Whereas overex-
pression of MYC and CSN5, individually, yielded only partial 
modulation of the wound signature genes, the simultaneous 
overexpression of both genes induced the synergistic tran-
scriptional response of a large fraction of the wound signature 
genes. This confirmed the functional role of this gene pair in 
regulating the prognostic wound signature phenotype.
This work by Adler and coworkers, as well as that of several 
others recently (Lamb et al., 2003; Wei et al., 2006; Miller et al., 
2005; Bild et al., 2006; Garraway et al., 2005; Sweet-Cordero et 
al., 2005) demonstrates that mechanistic discoveries are pos-
sible with microarray-based investigations if one searches the 
intersects of multiple data dimensions: transcription/genomic, bio-245
	 m i n i r e v i e wlogical/clinical, etc. (see Figure 1). Adler and coworkers focused 
on the interface between copy number and gene expression, and 
gene expression and patient survival, to discover transcriptional 
mechanisms in cancer with clinical significance. Other important 
discoveries have recently been made at the boundaries of gene 
expression, pathway activation, and genome-wide transcrip-
tion factor binding (Lamb et al., 2003; Wei et al., 2006; Miller 
et al., 2005; Bild et al., 2006). These studies also demonstrate 
the power of hypothesis building and testing between in vitro 
and in vivo systems, and even across species (Sweet-Cordero 
et al., 2005). To identify modifiers of Cyclin D1 activity, Lamb and 
coworkers (Lamb et al., 2003) identified a reproducible cassette 
of Cyclin D1-responsive genes in vitro and determined that a 
large fraction of these genes were significantly correlated with 
Cyclin D1 transcript levels in a panel of 190 tumors of mixed type 
(assessed by expression array analysis). The authors discovered 
that several transcription factors were both induced by Cyclin D1 
and correlated with Cyclin D1 overexpression in vivo. Further 
analysis of >380 tumors and cell lines from publicly available data 
sets revealed that one transcription factor in particular, C/EBPβ, 
remained significantly correlated with Cyclin D1 expression in 
different biological contexts. To test the hypothesis that C/EBPβ 
might modify cyclin D1 activity, the authors performed expression 
and promoter assays in cultured cells. Their results indicate that 
endogenous C/EBPβ acts as a constitutive repressor of Cyclin D1 
target gene promoters, thereby providing functional confirmation 
that C/EBPβ is a mechanism of Cyclin D1 action.
In another study, using a novel genomic technology called 
chIP-PET, Wei and coworkers (Wei et al., 2006) recently identi-
fied hundreds of novel bona fide p53 binding sites in the human 
genome. Genes adjacent to these binding sites were assembled 
as candidate direct target genes. They showed that the expres-
sion pattern in primary breast cancers of these new putative direct 
Figure 1. concept schematic of intersecting planes of genomic, biological, 
and clinical data that inform mechanistic discoveries.246 targets predicted for the mutational status of the p53 gene in these 
tumors and were prognostic of patient outcomes in human breast 
cancers. Similarly, we have described a 32-gene expression pro-
file that is closely associated with p53 status in human breast 
cancers and found that this profile can predict survival in breast 
cancer patients regardless of therapeutic intervention (Miller et 
al., 2005). Moreover, this p53 mutational cassette is associated 
with p53 mutations in hepatocellular carcinoma as well (Miller et 
al., 2005). In both examples, candidate cancer biomarkers were 
developed around a specific gene pathway and only afterwards 
associated with clinical outcome.
Forwarding this concept of pathway-specific expression sig-
natures, Bild and coworkers (Bild et al., 2006) used expression 
arrays to map multiple oncogenic pathway signatures in human 
cell line models. The signatures were then regressed into path-
way activity scores and validated in mouse mammary tumors 
derived from the activation of corresponding oncogenic pathways. 
In human tumors of different type, pathway activity scores were 
able to cluster tumors into groups associated with disease recur-
rence. Additionally, the pathway activity signatures could be used 
to predict the response of cell lines to drugs known to target spe-
cific components of the given oncogenic pathways. Thus, pathway 
signatures that gauge the activity of cancer-related pathways in 
vitro can serve as biological, prognostic, and therapeutic read-
outs in vivo.
This work by Adler et al. highlights the fact that the intersec-
tion of two genome-wide scans (expression and chromosomal 
amplification) can yield interesting higher-order mechanistic 
explanations for biological processes such as cancer. The weak-
ness still is that the process required investigator intervention to 
arrive at the candidate genes and is therefore subject to operator 
bias. For example, the 8q24 and 8q13 amplicons contain many 
other genes, but the selection of MYC and CSN5 was because 
of “expert” input. These were most likely selected because of 
the knowledge that MYC is an important oncogene in breast 
cancer behavior and that CSN5 is linked biochemically to post-
translational modification mechanisms that control MYC function. 
The investigators were fortunate that the two molecules when 
tested in vitro in model systems gave confirmatory results. Still, 
the possibility remains that other partners in the amplicon can 
give the same interactive outcome but for very different reasons. 
Therefore, it will be important to show that MYC and CSN5 have 
prognostic potential in other tumor sets from larger independent 
cohorts, and ultimately in prospective studies.
Nevertheless, this paper by Adler et al. highlights several 
larger principles in genomic medicine. In effect, they mapped 
the transcriptional control network for the wound response gene 
signature cassette in a complex system like human breast tumors 
and found that not one but two genetic elements, MYC and CSN5, 
had to be amplified in order for the cassette to be manifest. They 
therefore used a systems approach to identify components that 
provide a synthetic or conditional effect. Certainly synthetic 
lethality in genetic mutations is a well-known phenomenon in 
yeast genetics (Ooi et al., 2006). This is where the disruption of 
two genes gives a discernable phenotype when the knockout of 
either one has no effect. Such a principle has been proposed 
for cancer therapeutics (Kaelin, 2005). In addition, conditional 
response where the effect of a drug is dependent on the pres-
ence of another molecule that is not the target for the drug has 
been well described (Tan et al., 2005; Zhao et al., 2005). The 
MYC and CSN5 conditional interaction raises the possibility that cancer cell April 2006
	 m i n i r e v i e wtargeted inhibition of CSN5-mediated regulation of MYC might 
be a potential new therapeutic approach for breast cancer with 
MYC amplification. Thus, this systems approach to mapping tran-
scriptional control networks can provide pharmacological leads to 
targeted therapeutics that take advantage of cellular complexity. 
That MYC amplification is not found in normal tissues suggests 
that the therapeutic index of any such treatment targeting the 
CSN5-MYC interaction may be high.
Taken together, this work demonstrates that the intersection 
of orthogonal but precise data sets such as gene amplification 
and transcriptional expression on a genome-wide scale can pro-
vide insights into complex conditional interactions embedded in 
the systems map of cancer cell transcription.
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